{"date":"2025-10-07","count":6,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6875-2025-10-07-2222-1tccca7","company_id":"6875","company":"國邑*","market":"上櫃","industry":"生技醫療","date":"2025-10-07","time":"22:22:43","subject":"本公司L606授權夥伴Liquidia宣布將於2025年10月29日舉辦首屆研發日(R&D Day)並公布L606研發成果","clause":"第53款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：國邑*（6875），2025-10-07 22:22，「本公司L606授權夥伴Liquidia宣布將於2025年10月29日舉辦首屆研發日(R&D Day)並公布L606研發成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6499-2025-10-07-2028-1o6whnn","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2025-10-07","time":"20:28:42","subject":"公告本公司代理發言人異動案","clause":"第8款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：益安（6499），2025-10-07 20:28，「公告本公司代理發言人異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4114-2025-10-07-1832-yhktyw","company_id":"4114","company":"健喬","market":"上櫃","industry":"生技醫療","date":"2025-10-07","time":"18:32:23","subject":"公告本公司公開收購健亞生物科技股份有限公司普通股，公開收購期間屆滿","clause":"第38款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：健喬（4114），2025-10-07 18:32，「公告本公司公開收購健亞生物科技股份有限公司普通股，公開收購期間屆滿」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6986-2025-10-07-1706-1sxekfv","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2025-10-07","time":"17:06:12","subject":"本公司研發之異體間質幹細胞新藥HeXell-2020治療穩定型冠狀動脈疾病（CAD），向台灣衛生福利部食品藥物管理署（TFDA）提出Phase I／IIa人體臨床試驗申請","clause":"第44款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2025-10-07 17:06，「本公司研發之異體間質幹細胞新藥HeXell-2020治療穩定型冠狀動脈疾病（CAD），向台灣衛生福利部食品藥物管理署（T」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6564-2025-10-07-1500-11i1azz","company_id":"6564","company":"安特羅","market":"興櫃","industry":"生技醫療","date":"2025-10-07","time":"15:00:17","subject":"公告本公司與印尼ETANA公司簽訂腸病毒疫苗獨家經銷合約書","clause":"第8款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：安特羅（6564），2025-10-07 15:00，「公告本公司與印尼ETANA公司簽訂腸病毒疫苗獨家經銷合約書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2025-10-07-0638-1srz6xi","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2025-10-07","time":"06:38:47","subject":"代重要子公司Acepodia Biotech,Inc公告細胞新藥ACE1831用於第四型免疫球蛋白G相關疾病之Ib/IIa期臨床試驗獲得日本PMDA核准執行","clause":"第44款","fact_date":"2025-10-07","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2025-10-07 06:38，「代重要子公司Acepodia Biotech,Inc公告細胞新藥ACE1831用於第四型免疫球蛋白G相關疾病之Ib/II」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}